Home box 1484

Introducing New

PrevahexCHX Antimicrobial Dressing

Revolutionizing the Final Step of Infection Prevention

New PrevahexCHX™ is the first and only CHX dressing cleared by the FDA with complete antimicrobial protection throughout the transparent areas of the dressing. PrevahexCHX antimicrobial dressing incorporate groundbreaking technology utilizing pure chlorhexidine, providing rapid, broad-spectrum dressing protection at wound and catheter sites.

New evidence shows that catheter-related bloodstream infections (CRBSIs) and surgical site infections (SSIs) continue to cause unnecessary illness, healthcare costs and death in hospitals across the country. Research suggests that to better protect our patients, we may need to alter our approach.1

  • Infections

    2,000,000

    healthcare associated infections annually2

  • Green arrow
  • Lives lost

    80,000

    lives lost

  • Green arrow
  • Money

    $45B

    unnecessary healthcare costs2

  • Green arrow
  • Breakthrough

    1

    breakthrough solution

Research Highlights the Importance of Infection Prevention

  • Skin bacteria is the primary cause of infections.3
  • Skin antiseptics cannot sterilize the skin and they provide limited efficacy attributed, in part, to their poor permeation into the deeper layers of the skin.4
  • Post skin antisepsis regrowth of bacteria can occur within one day.5
  • Skin flora suppressed by skin antisepsis prior to catheter insertion can rapidly grow back and invade the wound.5
Skin

“The biggest draw for me to use this product was the Chlorhexidine antimicrobial component within the PrevahexCHX dressing to decrease the skin flora in the incisional area as the incision is commencing the healing process. There has not been any report of skin irritation, infection or rejection from any of the patients or nursing staff. Due to this experience, other members of our surgical staff are now also using PrevahexCHX.”

- John S. Foor M.D., F.A.C.S.

See Footnotes

1 Ryder, Marcia PhD. Healthcare Acquired Infections: Unfortunate Complication or Medical Error. Journal of Consumer Attorneys Associations for Southern California Advocate. July 2016

2 Stone, Patricia. Economic burden of healthcare-associated infections: an American perspective. Expert Rev Pharmacoecon Outcomes Res. October 2009; 9(5): pp. 417-422

3 Maki, D.G. Weise, C.E. Sarafin, H.W. A semiquantitative culture method for identifying intravenous-catheter-related infection. New England Journal of Medicine. 1977; 296(23): pp. 1305-1309. Maki, D.G. Alvarado, C.J. Ringer, M. Prospective randomized trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. The Lancet. 1991; 338(8763): pp. 339-343

4 Karpanen, T. Worthington, T. Conway, B. Hilton, C. Elliot, T. and Lambert, P. Penetration of Chlorhexidine into Human Skin. Antimicrobial Agents and Chemotherapy. October 2008; pp. 3633-3636

5 Reference: Maki, D.G., Cobb, L., Garman, J.K., Shapiro, J.M., Ringer, M., Helgerson, R.B. An attachable silver-impregnated cuff for prevention of infection with central venous catheters: A prospective randomized multicenter trial. Am J Med 1988; (85): pp. 307-314.